DR negativity is a distinctive feature of M1/M2 AML cases with NPM1 mutation

Meilani Syampurnawati; Eiji Tatsumi; Bambang Ardianto; Mariko Takenokuchi; Yuji Nakamachi; Seiji Kawano; Shun ichi Kumagai; Katsuyasu Saigo; Toshimitsu Matsui; Takayuki Takahashi; Ken ichi Nagai; Gunadi; Hisahide Nishio; Hiroki Yabe; Shin ichi Kondo; Yoshitake Hayashi

doi:10.1016/j.leukres.2007.11.017

DR negativity is a distinctive feature of M1/M2 AML cases with NPM1 mutation

Meilani Syampurnawati, Eiji Tatsumi, Bambang Ardianto, Mariko Takenokuchi, Yuji Nakamachi, Seiji Kawano, Shun ichi Kumagai, Katsuyasu Saigo, Toshimitsu Matsui, Takayuki Takahashi, Ken ichi Nagai, Gunadi, Hisahide Nishio, Hiroki Yabe, Shin ichi Kondo, Yoshitake Hayashi

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Our previous observation of a higher incidence of FLT3-ITD in DR^- M1/M2 AML than in DR⁺ M1/M2 led to an investigation of NPM1 mutation in the same samples, since DR^- AML and AML with NPM1 mutation share such characteristics as normal karyotype, the absence of CD34, and FLT3-ITD. NPM1 mutation was found in 18 of 26 (69.2%) of DR^- cases, but not in any of 28 DR⁺ cases. FLT3-ITD was noted in 66.7% of the cases with NPM1 mutation. These findings point to DR negativity as another phenotypic feature of AML with NPM1 mutation.

Original language	English
Pages (from-to)	1141-1143
Number of pages	3
Journal	Leukemia Research
Volume	32
Issue number	7
DOIs	https://doi.org/10.1016/j.leukres.2007.11.017
State	Published - Jul 2008
Externally published	Yes

Keywords

FLT3 mutation
HLA-DR-negative AML
NPM1 mutation

Access to Document

10.1016/j.leukres.2007.11.017

Cite this

Syampurnawati, M., Tatsumi, E., Ardianto, B., Takenokuchi, M., Nakamachi, Y., Kawano, S., Kumagai, S. I., Saigo, K., Matsui, T., Takahashi, T., Nagai, K. I., Gunadi, Nishio, H., Yabe, H., Kondo, S. I., & Hayashi, Y. (2008). DR negativity is a distinctive feature of M1/M2 AML cases with NPM1 mutation. Leukemia Research, 32(7), 1141-1143. https://doi.org/10.1016/j.leukres.2007.11.017

@article{a9238d4214f34f3c865aeb8fa7243b2f,

title = "DR negativity is a distinctive feature of M1/M2 AML cases with NPM1 mutation",

abstract = "Our previous observation of a higher incidence of FLT3-ITD in DR- M1/M2 AML than in DR+ M1/M2 led to an investigation of NPM1 mutation in the same samples, since DR- AML and AML with NPM1 mutation share such characteristics as normal karyotype, the absence of CD34, and FLT3-ITD. NPM1 mutation was found in 18 of 26 (69.2%) of DR- cases, but not in any of 28 DR+ cases. FLT3-ITD was noted in 66.7% of the cases with NPM1 mutation. These findings point to DR negativity as another phenotypic feature of AML with NPM1 mutation.",

keywords = "FLT3 mutation, HLA-DR-negative AML, NPM1 mutation",

author = "Meilani Syampurnawati and Eiji Tatsumi and Bambang Ardianto and Mariko Takenokuchi and Yuji Nakamachi and Seiji Kawano and Kumagai, {Shun ichi} and Katsuyasu Saigo and Toshimitsu Matsui and Takayuki Takahashi and Nagai, {Ken ichi} and Gunadi and Hisahide Nishio and Hiroki Yabe and Kondo, {Shin ichi} and Yoshitake Hayashi",

note = "Funding Information: The Special Cancer Research Fund from the Ministry of Education, Culture, Sports, Science and Technology supported this work. Bambang Ardianto, MD and Gunadi, MD, are receiving Japanese Government Scholarships for Graduate Student. We thank to Teguh Haryo Sasongko, MD, for the instructions and helps in using the dHPLC system.",

year = "2008",

month = jul,

doi = "10.1016/j.leukres.2007.11.017",

language = "English",

volume = "32",

pages = "1141--1143",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd.",

number = "7",

}

Syampurnawati, M, Tatsumi, E, Ardianto, B, Takenokuchi, M, Nakamachi, Y, Kawano, S, Kumagai, SI, Saigo, K, Matsui, T, Takahashi, T, Nagai, KI, Gunadi, Nishio, H, Yabe, H, Kondo, SI & Hayashi, Y 2008, 'DR negativity is a distinctive feature of M1/M2 AML cases with NPM1 mutation', Leukemia Research, vol. 32, no. 7, pp. 1141-1143. https://doi.org/10.1016/j.leukres.2007.11.017

TY - JOUR

T1 - DR negativity is a distinctive feature of M1/M2 AML cases with NPM1 mutation

AU - Syampurnawati, Meilani

AU - Tatsumi, Eiji

AU - Ardianto, Bambang

AU - Takenokuchi, Mariko

AU - Nakamachi, Yuji

AU - Kawano, Seiji

AU - Kumagai, Shun ichi

AU - Saigo, Katsuyasu

AU - Matsui, Toshimitsu

AU - Takahashi, Takayuki

AU - Nagai, Ken ichi

AU - Gunadi,

AU - Nishio, Hisahide

AU - Yabe, Hiroki

AU - Kondo, Shin ichi

AU - Hayashi, Yoshitake

N1 - Funding Information: The Special Cancer Research Fund from the Ministry of Education, Culture, Sports, Science and Technology supported this work. Bambang Ardianto, MD and Gunadi, MD, are receiving Japanese Government Scholarships for Graduate Student. We thank to Teguh Haryo Sasongko, MD, for the instructions and helps in using the dHPLC system.

PY - 2008/7

Y1 - 2008/7

N2 - Our previous observation of a higher incidence of FLT3-ITD in DR- M1/M2 AML than in DR+ M1/M2 led to an investigation of NPM1 mutation in the same samples, since DR- AML and AML with NPM1 mutation share such characteristics as normal karyotype, the absence of CD34, and FLT3-ITD. NPM1 mutation was found in 18 of 26 (69.2%) of DR- cases, but not in any of 28 DR+ cases. FLT3-ITD was noted in 66.7% of the cases with NPM1 mutation. These findings point to DR negativity as another phenotypic feature of AML with NPM1 mutation.

AB - Our previous observation of a higher incidence of FLT3-ITD in DR- M1/M2 AML than in DR+ M1/M2 led to an investigation of NPM1 mutation in the same samples, since DR- AML and AML with NPM1 mutation share such characteristics as normal karyotype, the absence of CD34, and FLT3-ITD. NPM1 mutation was found in 18 of 26 (69.2%) of DR- cases, but not in any of 28 DR+ cases. FLT3-ITD was noted in 66.7% of the cases with NPM1 mutation. These findings point to DR negativity as another phenotypic feature of AML with NPM1 mutation.

KW - FLT3 mutation

KW - HLA-DR-negative AML

KW - NPM1 mutation

UR - http://www.scopus.com/inward/record.url?scp=41949127653&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2007.11.017

DO - 10.1016/j.leukres.2007.11.017

M3 - Article

C2 - 18180033

AN - SCOPUS:41949127653

SN - 0145-2126

VL - 32

SP - 1141

EP - 1143

JO - Leukemia Research

JF - Leukemia Research

IS - 7

ER -

DR negativity is a distinctive feature of M1/M2 AML cases with NPM1 mutation

Abstract

Keywords

Access to Document

Fingerprint

Cite this